BioCeramic Therapeutics appoints new CEO
This article was originally published in Clinica
Executive Summary
Ian Brown has succeeded Daniel Green as CEO of BioCeramic Therapeutics (BCT), as the UK tissue regeneration products company enters its next stage of commercial growth. Mr Green, who has been at BCT since it was spun out of Imperial College, will remain as a board director. Mr Brown has held senior executive roles in both large multinationals and small- to medium-sized companies. His experience covers, among other things, M&A transactions and post-deal integration, fundraisings and IPOs. He joins London-based BCT as the firm is close to commercialising its first products, which include bioceramics for hard tissue treatment and flexible biomimetic scaffold for tissue engineering.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.